广泛耐药结核病现状及研究进展

摘要/Abstract

摘要： 自1993年世界卫生组织宣布结核病成为全球危机至今，结核病发病率和死亡率仍然居高不下，我国是结核病高负担国家，结核患者数居世界第2位，近几年来，肺结核均高居甲，乙类传染病报告发病数和死亡数前两位^[1-2]。

汪小黎,曹红艳,崔振玲,袁俐,胡忠义. 广泛耐药结核病现状及研究进展[J]. 中国防痨杂志, 2009, 31(11): 664-668.

[1] Zumla A, Mwaba P, Huggett J, Kapata N, Chanda D, Grange J. Reflections on the white plague[J]. Lancet Infect Dis, 2009,9(3):197-202.
[2] 王甦民，刘宇红，姜广路，刘洋，付育红，端木宏谨. 世界卫生组织中国结核病耐药监测的结果评价[J]. 中华检验医学杂志，2007，30(8)：863-866.
[3] World Health Organization.Global tuberculosis control and patient care:a ministerial meeting of high M/XDR-TB burden countries[R].Beijing,China,1-3 April,2009.http://www.who.int/tb_beijingmeeting/en/index.html
[4] DeAngelis CD, Flanagin A. Tuberculosis-a global problem requiring a global solution[J]. JAMA, 2005, 293(22): 2793-2794.
[5] Sarita Shah, Abigail Wright A, Fadila Boulahbal, Chris Gilpin, Francis Drobniewski, Gill-Han Bai, Marta Havelková, Rosario Lepe, Beverly Metchock, Maria Filomena Rodrigues, Franoise Portaels, Armand Van Deun, Sabine Rüsch-Gerdes, Véronique Vincent, Lucia Barrera, Kayla Laserson, Charles Wells, Peter Cegielski. Extreme drug resistance in tuberculosis (XDR-TB): Global survey of supranational reference laboratories for Mycobacterium tuberculosis with resistance to second-line drugs[J]. Int J Tuberc Lung Dis, 2005, 9 (1): 77.
[6] Centers for Disease Control and Prevention (CDC). Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs-Worldwide, 2000—2004[R]. MMWR Morb Mortal Wkly Rep, 2006, 55: 301-305.
[7] CDC. Revised definition of extensively drug-resistant tuberculosis[R]. MMWR Morb Mortal Wkly Rep, 2006, 55: 1176.
[8] Banerjee R, Allen J, Westenhouse J, Oh P, Elms W, Desmond E, Nitta A, Royce S, Flood J.Extensively drug-resistant tuberculosis in california, 1993—2006[J].Clin Infect Dis, 2008, 47(4): 450-457.
[9] Shah NS, Wright A, Bai GH, Barrera L, Boulahbal F, Martín-Casabona N, Drobniewski F, Gilpin C, Havelková M, Lepe R, Lumb R, Metchock B, Portaels F, Rodrigues MF, Rüsch-Gerdes S, Van Deun A, Vincent V, Laserson K, Wells C, Cegielski JP.Worldwide emergence of extensively drug-resistant tuberculosis[J]. Emerg Infect Dis, 2007, 13(3): 380-387.
[10] Bouvet E. Multidrug resistant tuberculosis: What is the risk in France[J]. Rev Prat. 2007, 57(13): 1405-1408.
[11] Masjedi MR, Farnia P, Sorooch S, Pooramiri MV, Mansoori SD, Zarifi AZ, Akbarvelayati A, Hoffner S. Extensively drug-resistant tuberculosis: 2 years of surveillance in Iran[J].Clin Infect Dis, 2006, 43(7): 841-847.
[12] Eker B, Ortmann J, Migliori GB, Sotgiu G, Muetterlein R, Centis R, Hoffmann H, Kirsten D, Schaberg T, Ruesch-Gerdes S, Lange C; German TBNET Group. Multidrug-and extensively drug-resistant tuberculosis, Germany[J]. Emerg Infect Dis, 2008, 14(11): 1700-1706.
[13] Mondal R, Jain A. Extensively Drug-Resistant Mycobacterium tuberculosis, India[J].Emerg Infect Dis, 2007, 13(9): 1429-1431.
[14] Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, Zeller K, Andrews J, Friedland G.Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa[J]. Lancet, 2006, 368(9547): 1575-1580.
[15] Kapp C. XDR tuberculosis spreads across South Africa[J]. Lancet, 2007, 369(9563): 729.
[16] Shah NS, Pratt R, Armstrong L, Robison V, Castro KG, Cegielski JP.Extensively drug-resistant tuberculosis in the United States, 1993—2007[J]. JAMA, 2008, 300(18): 2153-2160.
[17] World Health Organization.Global tuberculosis control: epidemiology, strategy, financing [R].WHO Report 2009.WHO/HTM/TB/2009.411
[18] Kam KM, Yip CW. Surveillance of Mycobacterium tuberculosis susceptibility to second-line drugs in Hong Kong, 1995—2002, after the implementation of DOTS-plus[J]. Int J Tuberc Lung Dis, 2004, 8(6): 760-766.
[19] Yu MC, Wu MH, Jou R. Extensively drug-resistant tuber-culosis, Taiwan[J]. Emerg Infect Dis, 2008, 14(5): 849-850.
[20] Zhao M, Li X, Xu P, Shen X, Gui X, Wang L, Deriemer K, Mei J, Gao Q.Transmission of MDR and XDR tuberculosis in Shanghai, China[J]. PLoS ONE, 2009, 4(2): e4370.
[21] Sun Z, Chao Y, Zhang X, Zhang J, Li Y, Qiu Y, Liu Y, Nie L, Guo A, Li C.Characterization of Extensively Drug-Resistant Mycobacterium tuberculosis Clinical Isolates in China[J]. J Clin Microbiol, 2008, 46(12): 4075-407.
[22] 李卫民，端木宏谨，王苏民，丁北川，刘宇红，姜广路，李传友.2000年中国结核病流行病学抽样调查菌株分子流行病学特征[J].中华医学杂志，2003，83(14)：1210-1213.
[23] Adjers-Koskela K, Katila ML. Susceptibility testing with the manual mycobacteria growth indicator tube (MGIT) and the MGIT 960 system provides rapid and reliable verification of multidrug-resistant tuberculosis[J].J Clin Microbiol, 2003, 41(3): 1235-1239.
[24] Huang TS, Lee SS, Tu HZ, Huang WK, Chen YS, Huang CK, Wann SR, Lin HH, Liu YC.Use of MGIT 960 for rapid quantitative measurement of the susceptibility of Mycobacterium tuberculosis complex to ciprofloxacin and ethionamide[J]. J Antimicrob Chemother, 2004, 53(4): 600-603.
[25] Costeira J, Pina J. Multi-drug resistant tuberculosis and the red queen-diagnosis speed is crucial[J]. Rev Port Pneumol, 2007, 13(6): 869-877.
[26] Moore DA, Mendoza D, Gilman RH, Evans CA, Hollm Delgado MG, Guerra J, Caviedes L, Vargas D, Ticona E, Ortiz J, Soto G, Serpa J; Tuberculosis Working Group in Peru. Microscopic observation drug susceptibility assay, a rapid, reliable diagnostic test for multidrug-resistant tuberculosis suitable for use in resource-poor settings[J]. J Clin Microbiol, 2004, 42(10): 4432-4437.
[27] Brady MF, Coronel J, Gilman RH, Moore DA.The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis[J]. J Vis Exp, 2008, (pii): 845.
[28] 金文国，胡忠义. 显微镜观察药物敏感性检测技术及其在结核病诊断和耐药性检测中的应用[J]. 中华预防医学杂志，2008，42(2)：134-136.
[29] 付佑辉, 钭方芳, 郑瑞娟, 王洁, 金文国, 胡忠义. MODS技术快速检测结核分枝杆菌左氧氟沙星耐药性研究[J]. 临床肺科杂志，2009，14(2)：154-155，157.
[30] Chan RC, Hui M, Chan EW, Au TK, Chin ML, Yip CK, AuYeang CK, Yeung CY, Kam KM, Yip PC, Cheng AF.Genetic and phenotypic characterization of drug-resistant Mycobacterium tuberculosis isolates in Hong Kong[J].J Antimicrob Chemother,2007,59(5):866-873.
[31] Mukaigawa J, Endoh M, Yanagawa Y, Morozumi S.Anti-drug pattern of drug-resistant Mycobacterium tuberculosis and analysis of mutation in drug-target genes[J]. Kansenshogaku Zasshi, 2005,79(6):388-396.
[32] 唐神结，肖和平. 严重耐药结核病的研究进展[J].中华结核与呼吸杂志，2009,32(5):380-383.
[33] Mukherjee JS, Rich ML, Socci AR, Joseph JK, Virú FA, Shin SS, Furin JJ, Becerra MC, Barry DJ, Kim JY, Bayona J, Farmer P, Smith Fawzi MC, Seung KJ. Programmes and principles in treatment of multidrug-resistant tuberculosis[J]. Lancet,2004, 363(9407): 474-481.
[34] Van Deun A, Salim MA, Das AP, Bastian I, Portaels F. Results of a standardised regimen for multidrug resistant tuberculosis in Bangladesh[J]. Int J Tuberc Lung Dis, 2004, 8(5): 560-567.
[35] Leimane V, Riekstina V, Holtz TH, Zarovska E, Skripconoka V, Thorpe LE, Laserson KF, Wells CD. Clinical outcome of individualised treatment of multidrug resistant tuberculosis in Latvia: A retrospective cohort study[J].Lancet, 2005, 365(9456): 318-326.
[36] Bonilla CA, Crossa A, Jave HO, Mitnick CD, Jamanca RB, Herrera C, Asencios L, Mendoza A, Bayona J, Zignol M, Jaramillo E.Management of extensively drug-resistant tuberculosis in Peru: cure is possible[J].ePLoS ONE, 2008, 3(8): e2957.
[37] Sotgiu G, Ferrara G, Matteelli A, Richardson MD, Centis R, Ruesch-Gerdes S, Toungoussova O, Zellweger JP, Spanevello A, Cirillo D, Lange C, Migliori GB.Epidemiology and clinical management of XDR-TB: a systematic review by TBNET[J].Eur Respir J, 2009, 33(4):871-881.
[38] Koenig R.Drug-resistant tuberculosis. In South Africa, XDR-TB and HIV prove a deadly combination[J]. Science, 2008, 319(5865): 894-897.
[39] Loman NJ, Pallen MJ. XDR-TB genome sequencing: a glimpse of the microbiology of the future[J]. Future Microbiol, 2008, 3(2): 111-113.

广泛耐药结核病现状及研究进展

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 0

编辑推荐

Metrics

本文评价

友情链接